Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tango Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies focused on synthetic lethality and immunotherapy. The company's lead programs include TNG908 (a PRMT5 inhibitor for MTAP-deleted tumors) and TNG462 (a USP1 inhibitor), both in Phase 1/2 trials targeting genetically defined patient populations. With no commercial revenue and $-100M annual cash burn, the stock trades on clinical trial readouts, regulatory milestones, and partnership potential.
Tango operates a discovery-to-clinic model focused on synthetic lethality, where genetic alterations in tumors create dependencies on specific pathways. The company identifies tumor vulnerabilities through computational biology and develops small molecule inhibitors. Revenue generation depends on successful clinical trials (Phase 1/2 currently), FDA approval, and eventual commercialization or out-licensing. The MTAP deletion target (TNG908) represents approximately 15% of solid tumors, providing significant addressable market if clinical efficacy is demonstrated. Pricing power will depend on clinical differentiation versus existing standards of care and competitive targeted therapies.
Clinical trial data readouts for TNG908 (PRMT5 inhibitor) and TNG462 (USP1 inhibitor) - objective response rates, progression-free survival
FDA regulatory milestones including IND clearances for new programs and breakthrough therapy designations
Strategic partnerships or licensing deals with large pharmaceutical companies providing validation and non-dilutive funding
Equity financing announcements and cash runway extensions - dilution concerns versus survival probability
Competitive clinical data from rival synthetic lethality programs (e.g., Mirati, Kura Oncology)
Biotech sector sentiment and risk appetite for pre-revenue assets
Clinical trial failure risk - Phase 1/2 assets have 10-15% probability of eventual FDA approval based on industry statistics
Synthetic lethality mechanism validation - novel approach with limited precedent of commercial success outside PARP inhibitors
Regulatory pathway uncertainty for genetically defined subpopulations requiring companion diagnostics
Reimbursement challenges for targeted therapies in fragmented patient populations (MTAP deletion testing requirements)
Multiple competitors developing PRMT5 inhibitors (Mirati's MRTX9768) and USP1 inhibitors with potentially faster timelines
Large pharmaceutical companies with superior resources entering synthetic lethality space
Alternative treatment modalities (immunotherapy combinations, ADCs) addressing same patient populations
Patent expiration risks and freedom-to-operate challenges in crowded targeted oncology space
Cash burn of $100M annually requires equity raises every 24-30 months creating dilution risk
Current 8.88x current ratio and $350M+ cash provides runway into 2028, but clinical setbacks accelerate financing needs
22% debt-to-equity ratio is manageable but any debt covenants could restrict operational flexibility
Negative 60.8% ROE and 47.8% ROA reflect pre-revenue status - no path to profitability before 2030 at earliest
low - Clinical trial timelines and FDA processes are largely insulated from GDP fluctuations. However, financing conditions for capital raises are affected by risk appetite. Severe recessions can delay partnership discussions as pharma companies reduce business development activity.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-10+ years until potential profitability). Higher rates also increase opportunity cost of holding non-yielding, cash-burning growth stocks versus fixed income. Financing costs for future debt raises increase, though equity remains primary funding source. The 432% one-year return suggests momentum-driven trading amplifies rate sensitivity.
Minimal direct credit exposure. Company maintains cash in short-duration treasuries and money market funds. Access to equity capital markets is critical - tightening credit conditions reduce biotech IPO/follow-on activity and increase dilution required for raises. High-yield spreads serve as proxy for risk appetite affecting biotech valuations.
growth - Pure clinical-stage speculation attracting biotech-focused hedge funds, venture capital crossover funds, and retail momentum traders. The 432% one-year return indicates heavy momentum/technical trading. Not suitable for value or income investors given no earnings, dividends, or tangible book value. Requires high risk tolerance and 5-10 year investment horizon for binary clinical outcomes.
high - Clinical-stage biotech with binary event risk (trial readouts move stock 30-50%). Recent 61.8% three-month return demonstrates extreme volatility. Low float and institutional concentration amplify price swings. Estimated beta >2.0 versus broader market. Options market likely prices high implied volatility around data catalyst dates.
